Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

In a new application study, Postnova Analytics reports that its latest generation of Asymmetrical Flow Field Flow Fractionation (AF4) systems are providing labs worldwide with a uniquely powerful technique to characterize and quantitate virus and virus-like particles.

Characterizing virus and virus-like particles

Virus and virus-like particles are widely used in the healthcare industry for vaccination via immune response stimulation. Because these particles are to be injected into patients there is a critical requirement for a technique that allows detection and separation of the monomeric, oligomeric and aggregated species in a typical formulation.

Although Size Exclusion Chromatography (SEC) has been a traditional analytical technique used for this application it has significant limitations relating to the size exclusion limit of the separation column that restricts the upper molar mass and particle size range that can be measured.

By comparison, AF4 is an advanced separation technique that can address the problems associated with SEC. In AF4, an open, unpacked separation channel is used in place of a packed column. The absence of a stationary phase in AF4 systems results in the ability to use a wider range of solvents, elimination of SEC shear force and matrix interaction effects as well as the ability to separate particles over a very wide size range, from 1 nm up to above 1 µm. These capabilities enable AF4 to provide a complete picture of virus and virus-like particles including monomer content, insoluble and soluble aggregates, as well as the subvisible particle fraction.

Read More

Related categories

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more 
Evotec expands into gene therapy with new Austrian unit

Evotec expands into gene therapy with new Austrian unit

6 Apr 2020

Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.

Read more